CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country

Sulaiman, Noor Yuhyi; Anuar, Nur Adila; Arshad, Normala; Cheong, Chin Sum; Liong, Chee Chiat; Khairullah, Shasha; Chin, Edmund Fui Min; Bee, Ping Chong; Sam, I Ching; Iyadorai, Thevambiga; Gan, Gin Gin

doi:10.1007/s12288-023-01655-0

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, epidemiological studies in this region are limited. To date, data from a few published studies in this region have reported the prevalence of CMV infections in post‐AHSCT patients ranged from 35% to 48.7% [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation

Gan,

Iyadorai,

Sulaiman

et al. 2024

Clinical Transplantation

Self Cite

View full text Add to dashboard Cite

BackgroundCytomegalovirus infection (CMV) is a common complication after allogeneic hematopoietic stem cell transplantation (AHSCT). CMV infection increases transplantation costs; however, the extent of the financial burden may vary in different countries. This study aims to determine the clinical and economic impact of CMV infection in patients undergoing AHSCT in a middle‐income country.MethodsA total of 150 adult and pediatric patients post‐AHSCT were included for analysis. In addition to incidence of CMV infections, data on graft versus host disease (GVHD) were also collected. Standard hospital charges for AHSCT and any additional transplantation‐related expenditure within 12 months were also retrieved in 104 patients.ResultsCMV infection, acute GVHD and chronic GVHD occurred in 38.7%, 60.7%, and 22.0% of patients, respectively. Patients with CMV infections had higher readmission rates compared to those who did not (67.2% vs. 47.8%; p = 0.020). Additional expenditure was seen in HLA‐haploidentical AHSCT and CMV infection (MYR11 712.25/USD2 504.49; p < 0.0001 and MYR5 807.24/USD1 241.79; p = 0.036), respectively.ConclusionThis single‐center study demonstrated that patients who underwent HLA‐haploidentical AHSCT and subsequently developed CMV infection had higher transplantation expenditures compared to those who had matched‐related transplantation. Further studies should be conducted to evaluate if primary prophylaxis against CMV is cost‐effective, especially in patients who undergo HLA‐haploidentical AHSCT.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation

Gan,

Iyadorai,

Sulaiman

et al. 2024

Clinical Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT

Siemaszko,

Dratwa,

Szeremet

et al. 2024

Archivum Immunologiae Et Therapiae Experimentalis

View full text Add to dashboard Cite

The aim of the present study was to determine the associations between the MICB genetic variability and the expression and the risk of development of post-transplant complications after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT recipients and their donors were genotyped for two MICB polymorphisms (rs1065075, rs3828903). Moreover, the expression of a soluble form of MICB was determined in the recipients' serum samples after transplantation using the Luminex assay. Our results revealed a favorable role of the MICB rs1065075 G allele. Recipients with donors carrying this genetic variant were less prone to developing chronic graft-versus-host disease (cGvHD) when compared to recipients without any symptoms of this disease (41.41% vs. 65.38%, p = 0.046). Moreover, the MICB rs1065075 G allele was associated with a lower incidence of cytomegalovirus (CMV) reactivation, both as a donor (p = 0.015) and as a recipient allele (p = 0.039). The MICB rs1065075 G variant was also found to be associated with decreased serum soluble MICB (sMICB) levels, whereas serum sMICB levels were significantly higher in recipients diagnosed with CMV infection (p = 0.0386) and cGvHD (p = 0.0008) compared to recipients without those complications. A protective role of the G allele was also observed for the rs3828903 polymorphism, as it was more frequently detected among donors of recipients without cGvHD (89.90% vs. 69.23%; p = 0.013). MICB genetic variants, as well as serum levels of sMICB, may serve as prognostic factors for the risk of developing cGvHD and CMV infection after allogeneic HSCT.

show abstract

CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country

Cited by 2 publications

References 26 publications

Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation

Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation

MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT

Contact Info

Product

Resources

About